A groundbreaking study led by researchers from Columbia Data Analytics, Bogazici University and the City University of New York (CUNY) College of Technology, has demonstrated that semaglutide, a GLP-1 receptor agonist, significantly reduces the risk of major kidney disease events among patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) in real-world clinical practice.
Key Findings
An external control arm study using real-world data was constructed; rigorous statistical methods were applied including propensity score matching and Cox regression, to ensure comparability with the FLOW trial population. The primary outcome was a composite of kidney failure onset and a sustained 50% reduction in estimated glomerular filtration rate.
“These results provide compelling real-world evidence for the use of semaglutide in reducing the risk of kidney failure and progression in patients with type 2 diabetes and CKD,” said lead author Dr. Onur Baser. “The findings support broader adoption of semaglutide as a renoprotective therapy and may inform clinical guidelines, payer coverage decisions, and health policy.”
Although reliance on diagnosis codes and the inability to confirm medication adherence are limitations typical of observational research, the large sample size, advanced statistical adjustments, and consistency with clinical trial data strengthen the findings’ validity.
26% Reduction in Major Kidney Events:
Compared with standard care, semaglutide treatment was associated with a 26% reduction in the risk of major kidney disease events, including kidney failure and substantial loss of kidney function. This effect is consistent with, and slightly exceeds, the 24%risk reduction observed in the landmark FLOW clinical trial
Robust Real-World Evidence:
Creating 896,257 external control arm semaglutide users and a comparator group from the Kythera Labs database (2019–2024), the study provides the largest real-world evaluation of semaglutide’s renoprotective effects to date.
Broad Patient Representation:
The real-world cohort included a more diverse, representative patient population than typical clinical trials, enhancing the generalizability of the findings.
Consistent Results Across Sensitivity Analyses:
The study’s conclusions remained robust across multiple sensitivity analyses, further supporting the reliability of the results.
Read all of our latest publications.
Follow us for more HEOR news.
